AI is speeding up preclinical drug development at a fraction of the cost
Louis comments that AI is accelerating the early stages of drug development, including with free or low-cost tools. The shared content is unavailable and no evidence is cited.
2 posts
Louis comments that AI is accelerating the early stages of drug development, including with free or low-cost tools. The shared content is unavailable and no evidence is cited.

Louis notes that cyclodextrin, a controversial alternative heart disease treatment, may help treat Alzheimer's, with a news item on an MIT patent deal targeting brain cholesterol transport in ApoE4-linked disease.